• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

QT Vascular launches pivotal trial for drug-coated peripheral balloon

July 31, 2017 By Sarah Faulkner

QT VascularQT Vascular said today that it launched the U.S. pivotal trial for its Chocolate Touch drug-coated peripheral balloon in the hopes of winning FDA approval. The device won CE Mark clearance in September 2015.

The trial is slated to compare the safety and effectiveness of the Chocolate Touch balloon with Bard‘s(NYSE:BCR) Lutonix drug-coated balloon catheter. The company said it plans to evaluate non-inferiority and superiority of its DCB over Bard’s device.

QT Vascular plans to enroll 510 patients and complete an interim analysis after 75% of the participants finish a 12-month follow-up. The study’s primary efficacy endpoint is primary patency in the absence of bailout stenting, according to the Singapore-based company.

“I’m delighted to start enrollment in this important study,” co-principal investigator Thomas Zeller said in prepared remarks. “We believe that the unique properties of Chocolate, namely larger lumen with less dissections and bailout stenting, make this a differentiated DCB option. This head-to-head study against Lutonix DCB is set up to demonstrate this point.”

“We are excited about the first patient enrollment in this worldwide study evaluating Chocolate, a second-generation DCB,” co-principal investigator Mehdi Shishehbor added. “This first of a kind trial will help guide physicians as they choose the best DCB for their patients.”

In the Chocolate Touch Endure study, 12-month outcomes included a 1.4% incidence of bailout stenting.

“DCBs are demonstrating significant US sales despite limitations and lack of differentiation,” CEO Eitan Konstantino said. “The Chocolate platform is different and we are encouraged by the clinical results to date.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Vascular, Wall Street Beat Tagged With: C.R. Bard, QT Vascular

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS